Memorandum
RE:
Tamara laments that upon trying various diets and many pills in sought for reducing weight, all her efforts have been futile. She is still earning those extra pounds even though she is starving and the weight loss pills do not seem to work. According to her, she could give anything just to get a former weight back.
Background
Barbara Printup-a senior marketing director for Cambridge Sciences Pharmaceuticals (CSP) paid attention to various overweight people as they narrated their numerous struggles to offset overweight. Due to this, he has been appointed to be in charge of the launching of a new weight loss drug-Metabical. Clinical tests have proved Metabical to be effective in weight loss moderation for averagely overweight people and very safe.
Recommendation
CSP’ Metabical is the best drug that has been approved by the FDA and is specific for those individuals who are overweight specifically those ones whose BMI lies between 25 and 30.
Basis for recommendation
- The CSP researchers made a drug creation that combined a compound that was an appetite-suppressant, calosera which also had a revolutionary calorie-absorption and fat-blocking agent, meditonan. This combination of meditonan and calosera worked magically on the weight loss of overweight individuals.
- Metabical works on a low-dose formulation hence reduces stress on the liver and heart functions that tended to be produced by other weight loss drugs.
- Metabical also had a controlled-release feature whose requirement was just one pill per day.
Assumptions and risks
The drug’s negative side effects were evident when the drugs users took a diet with high fat and calories’ levels. These were just like gastrointestinal discomfort only that they were less severe. However, metabical clinical tests proved that the drug was effective for one to achieve significant weight loss. Studies showed that those individuals who had a BMI of 28 to 30 were able to lose an average of 26 pounds upon taking Metabical in comparison to an average of 6 pounds for those individuals lying within the same BMI range that took a Placebo.
Exhibit 1 Trends: percentage of Overweight, Obese, and Severely Obese Adults in the United States, 1976-2001
